FyoniBio Introduces CHOFlow® for High-Yield Production of Afucosylated ADCC-Enhanced Antibodies
FyoniBio has launched CHOFlow®—a new addition to its tailored cell line portfolio designed to produce afucosylated antibodies with enhanced ADCC activity. Built on the proven CHOnamite® platform and integrated with glyco-engineering technology, CHOFlow® enables high-yield, stable production of antibodies and glycoproteins with potential applications in cancer, infectious disease, and autoimmune therapies.
